ABL Bio to Hold YouTube Live Corporate Presentation on the 8th

ABL Bio.

[Asia Economy Reporter Lee Gwan-ju] ABL Bio, a bispecific antibody specialist company, announced on the 4th that it will hold a live corporate presentation (IR) through its YouTube channel at 12 noon on the 8th.

This presentation was planned to create a communication platform with interested investors, including its shareholders, as interest in the company increased following the signing of a technology transfer agreement for the Parkinson's disease treatment candidate 'ABL301.'

At this event, ABL Bio plans to share the significance of the ABL301 contract, the current status of major research and development, and the company's short- and mid-to-long-term vision. Some questions and suggestions received through YouTube live chat will be selected for a Q&A session. CEO Lee Sang-hoon will personally handle the presentation and the Q&A.

CEO Lee said, "We are holding this corporate presentation to strengthen the trust relationship between ABL Bio and its shareholders through active communication and to enhance shareholder value," adding, "We will continue to provide such communication opportunities in the future."

Meanwhile, ABL Bio is a bispecific antibody specialist company developing next-generation immuno-oncology drugs and treatments for degenerative brain diseases.

This content was produced with the assistance of AI translation services.